George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Nothing changes. The official RNS is the only thing you can be sure of.
And we are awaiting it.
Then the next flow test to wait on.....
Note there are two flow tests. We are awaiting the result of the 1st one. 2nd one follows, is it 10 days later?
Won't be long until news. Bound to get some oil I think......... just how much.
In fact why would they NOT be interested in buying Angle Plc? Same goes for any Co. that currently offers molecular analysis of blood.
Illumina (and 50 or so others like Thermo Fisher) have the hardware and software to identify actionable DNA variants.
Their systems are used to do this every day, but from a general blood sample. DNA varients can be targeted by modern cancer treatments. Angle's Parsortix system gives their clients the opportunity (if they have a parsortix machine) to do the same with the circulating tumour cells in addition to the general blood. Parsortix can catch these from the same standard blood sample. See Angle Plc's RNS announcements 4th and 20th Jan this year. More accurate than sampling general blood then. 99% of the circulating tumour cells Parsortix can catch are ***LIVE and intact***. I don't see how you could get a better sample of the tumour to test. So is it not the case that testing circulating tumour cells to find actionable DNA variants is the next step forward??
Surely offering this addition would increase Illumina's sales (or Thermo Fishers etc...). Seems obvious to me.
We know Angle have talked to Illumina about the results of testing the CTC's. I suspect they will have talked to Thermo Fisher and any other Company in the same field by now. One is bound to do some sort of deal IMHO. Just a metter of time. From Illumina's web site:-
https://emea.illumina.com/content/dam/illumina-marketing/documents/products/appspotlights/ngs-liquid-biopsy-app-spotlight-1170-2019-007.pdf
All IMHO.
Gulp!
Moab.
"No, Carrot, I am not a troll. I just find pointless repetition rather irritating, (as at 10.40 and 10.41) as I suspect do others. I also prefer posts to be accurate, and to the point. I have read the .pdf carefully which I why I made my post @ 10.08. I am not trying to provoke anything beyond an explanation. I repeat; what was your point in drawing attention to this.pdf?".
========================================
Are you sure you are not having a laugh? I honestly think you are. Or you want me to explain the relevance because you have a long position and don't think some on here would understand it? Is that it??
The Illumina web page (see link below) is entitled "Liquid Biopsy and NGS: Driving translational clinical research to the next level". The ***"NEXT LEVEL"***. You do know what a liquid biopsy is don't you? You simply must know that Angle's machine can catch a single LIVE intact circulating tumour cell (ctc) from a standard blood sample. 99% caught using their Parsortix machine are LIVE and intact, ideal for analysing. Other competing systems often kill and/or and damage the ctc.
Angle Plc's RNS announcements of 4th and 20th Jan 2024 say they found "actionable DNA variants" in the circulating tumour cells that could not be found in the same persons CtDNA blood plasma test (general blood test to find, then test for actionable CtDNA). Even though both tests were done using ONE BLOOD SAMPLE FROM THE SAME PERSON. Exactly the same NGS methods were used. According to Angle that was previously either unknown, or I think had been noticed in some study's but it's significance not appreciated. Does in not occur to you that "the next level" may well, no, is likely to include analysing the cct's for "actionable DNA variants"? Actionable DNA variants being DNA that can be ****targeted by modern drugs to help cure cancer****.
Some extracts from the Illumina article:-
"Next-generation sequencing (NGS) methods enable highly sensitive and specific detection of known mutations."
As per Angle's RNS's they found some of these in the CtC's.
"More recently, comprehensive assays are being developed to analyse a wider range of candidate genes and variant types for new tumour’s that do not have known variants. As these methods evolve, ctDNA analysis for various applications such as screening, therapy selection, monitoring, and identification of therapy resistance is gaining prominence as a method for monitoring disease state."
https://emea.illumina.com/content/dam/illumina-marketing/documents/products/appspotlights/ngs-liquid-biopsy-app-spotlight-1170-2019-007.pdf
All IMHO.
Are you a "troll", which I understand is someone who likes to annoy other people?
I'm not going to reply to you provocation. People can read this Illumina page about liquid biopsies and judge for themselves. Have you even read it? LOL!
https://emea.illumina.com/content/dam/illumina-marketing/documents/products/appspotlights/ngs-liquid-biopsy-app-spotlight-1170-2019-007.pdf
U sure Illumina won't bid for Angle Plc?!!!!
From Illumina's web site:-
https://emea.illumina.com/content/dam/illumina-marketing/documents/products/appspotlights/ngs-liquid-biopsy-app-spotlight-1170-2019-007.pdf
Hello.
Moab & Thompi.
If you do a search on google for "what can ctdna tell you about a cancer?" you get this:-
"ctDNA can be used to test for changes in biomarker status which can lead to a change in treatment. ctDNA can be measured in blood to identify the presence of residual cancer cells after surgery or to monitor for cancer recurrence after successful treatment.".
Moab.
You stated:- "The ctDNA test is not aimed at finding actionable varients as incomplete fragments of DNA may be either useless or unhelpful because they are a tiny, tiny fragment of all the DNA that is in plasma as a result of cell apoptosis.".
I see. So the ctdna analysis of the blood plasma is more general test but not specific enough to find actionable DNA varients? Thanks for correcting me there. I only want to find the facts, not distort them.
Then you stated this: "I do not deny the contents of the RNS, but it is bleedingly obvious that more info is going to come from an intact tumour cell than an incomplete shred of DNA in plasma.".
I'm glad you agree live CCT's offer a lot more information, ***including sometimes actionable DNA varients*** as Angle have stated in their RNS's. This is why IMHO Companies like Illumina should be adding to their offering analysing the LIVE circulating tumour cells (CTC's). As you are aware Angle's Parsortix machine can catch LIVE intact CCT's which can be tested by the likes of Illumina's hardware to find if they contain any actionable DNA varients. These DNA varients might then be targeted by modern cancer treatment methods. This is why the sp spiked to 37p on 4th Jan. Very good. In conclusion it seems totally obvious to me that all the Companies who currently sell CtDna analysis machinines will want to add the analysys of CCT's!!!!!!!!!!!!!!!!! The next RNS should be interesting !
All IMHO.
Moab.
In reply to your post.
1, What original question?
2. Why have you not answered the subject title question above. If there is a valid reason then I'd like to know. Even if it is bad news!
3. Angle's RNS's of 4th Jan and 20th Jan are basically saying they have found "actionable DNA varients" in LIVE circulating tumour cells (CTC's) that were NOT found when the same patients blood plasma DNA fragments were tested (the CtDNA). Do you deny that is what the RNS says? Actionable DNA, as I understand it, is DNA that, if found in the cancer can be targeted by certain treatments? Do you deny this? You may have mis-understood my posts. This discovery was only anounced on 4th Jan! I was trying to say this. IN THE FUTURE, the likes of the Illumina system might be used to find any actionable DNA varients in both the CtDna and the CCT's. Those actionable variants might then be targeted with treatments. Note the information from CtDNA analysis is already currectly used to guide clinicians as I understand it. Adding the CCT analysis seems the next logical step, and that seems to be what Angle are suggesting. That is why, as they said in the RNS, they are discussing this with Illumina.
All IMHO.
15 mins to get in if you want.
If positive news leaks over the weekend the sp will start Moday way higher than 0.35p IMHO.
I think early next week the sp will break .40p.
Next Thursday (21st). They will have a good idea well before than I suspect. Next Wednesday??
This dip may be the lowest it goes........... for years!!
Moab.
If I had metastasized cancer (spread, or in the blood supply trying to re-seed) and I had for example an Illumina CtDNA test so the clinician could decide what treatment I should have I would want it to be as accurate as possible. The CtDNA test is to find actionable DNA variants. These are usually found by analysing DNA fragments of dead cells which naturally and up in blood plasma before being excreted. Some of these fragments are from the cancer tumour. Some treatments can TARGET these variants (therefore the cancer) slowing down the spread, possibly stopping it. Angle have shown that sometimes there are STILL actionable DNA variants in circulating cancer cells WHEN NONE ARE FOUND in the standard CtDNA test!!!!!!! Therfore Angle are suggesting ALL the Companies IN THE WORLD that already offer CtDNA analysis of the DNA fragments in blood plasma ALSO offer the same analysis of the circulating cancer cells. Clearly if a circulating cancer cell is STILL in the blood supply and it has actionable DNA variants that might be TARGETED by treatment it is rather important, to say the least!!
Clearly the stock market totally fails at the moment to appreciate this!!
Once Angle get the firrst Molecular analysis Co. on board this will massively change IMHO.
All IMHO.
Looks like the market has decided they are way undervalued.
Moab.
Please filter my posts. I have no interest at all in anything you say.
I find it totally astonishing that Molecular analysis Co's in the World, including Illumina Inc. of USA, seemed to be totally unaware that DNA sequencing CtDNA does NOT give the full picture of a patients cancer that has metastasized. Angle's RNS's dated 4th Jan and 22nd Jan show that also DNA sequencing LIVE circulating tumour cells (that Angles's Parsortix machine can catch in a matter of hours) can sometimes find actionable DNA variants in the cct's! Actionable DNA variants NOT FOUND in the CtDNA! These actionable DNA variants can be targeted for treatment by ****some treatments currently available****. Therefore clearly some patients with actionable DNA in their cancer have, and are still being missed.
Illumina and the other Co's in this field really need to sort this out.
- I'm sure Angle Plc will be willing to discuss ways forward with this.
All IMHO.
Ikhan1284.
"It's totally luck 😹 I will buy 50 million shares and see what happens".
======================
I'm waiting to see this.
This! LOL!